5.62

4.94% 0.1026

Cns Pharmaceuticals Inc (CNSP)

Overview News Price History Financials Discussions Forecast Stock Split

Cns Pharmaceuticals Inc stock is traded at $5.62, with a volume of 2,304. It is up +4.94% in the last 24 hours and up +14.20% over the past month. CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.

Previous Close:

$5.5174

Open:

$5.7

24h Volume:

2,304

Relative Volume:

0.08

Market Cap:

$8.46M

Revenue:

Net Income/Loss:

$-16.49M

P/E Ratio:

-0.1897

EPS:

-29.6295

Net Cash Flow:

$-15.24M

1W Performance:

-0.69%

1M Performance:

+14.20%

6M Performance:

+86.17%

1Y Performance:

-7.58%

1-Day Range:

$5.4774

$5.79

1-Week Range:

$5.44

$6.1899

52-Week Range:

$1.90

$10.59

Cns Pharmaceuticals Inc Stock (CNSP) Company Profile

Name

Cns Pharmaceuticals Inc

Sector

Healthcare (1088)

Industry

Biotechnology (605)

Phone

1-800-946-9185

Address

2100 WEST LOOP SOUTH, HOUSTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

CNSP's Discussions on Twitter

Compare CNSP vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CNSP Cns Pharmaceuticals Inc	5.79	8.77M	0	-16.49M	-15.24M	-29.63
VRTX Vertex Pharmaceuticals Inc	541.81	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	789.92	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,030.35	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	136.40	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	206.80	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-24-20	Initiated	Ladenburg Thalmann	Buy

Cns Pharmaceuticals Inc Stock (CNSP) Latest News

Aug 19, 2026

CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com South Africa

Aug 19, 2026

Aug 18, 2026

Vertical Data: Downs Most Recently Served as CFO of CNS Pharmaceuticals >VDTA - Moomoo

Aug 18, 2026

CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock - Investing.com

Aug 18, 2026

CNS Pharmaceuticals (CNSP) director buys 2,000 shares in open-market trade - Stock Titan

Aug 18, 2026

CNS Pharmaceuticals (CNSP) CEO converts 4,750 RSUs to stock - Stock Titan

Aug 18, 2026

Aug 17, 2026

Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com

Aug 17, 2026

Aug 16, 2026

CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Trade Setups - vinanet.vn

Aug 16, 2026

Aug 14, 2026

Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan

Aug 14, 2026

Aug 13, 2026

CNSP Q2 2026 Earnings: Wider-than-Expected Loss of -$0.38 per Share Amid Clinical-Stage OperationsNet Profit Margin - vinanet.vn

Aug 13, 2026

Aug 12, 2026

CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

Aug 12, 2026

CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo

Aug 12, 2026

CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView

Aug 12, 2026

CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView

Aug 12, 2026

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com

Aug 12, 2026

CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView

Aug 12, 2026

CNS Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo

Aug 12, 2026

CNS Pharmaceuticals Q2 FY26 net loss widens 9% to $2.59 million year over year - Bitget

Aug 12, 2026

Aug 11, 2026

CNSP Q1 2026 Earnings: Loss of $7.30 Per Share Misses Estimates as Pre-Revenue Pipeline Spend Rises - vinanet.vn

Aug 11, 2026

Aug 10, 2026